Involvement of COL5A2 and TGF‑β1 in pathological scarring
- Authors:
- Published online on: July 27, 2021 https://doi.org/10.3892/etm.2021.10501
- Article Number: 1067
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Dysregulation in the cutaneous wound‑healing process is a consequence of alterations in the efficiency and activity of the various components involved in the healing process. This dysregulation may result in various clinical appearances of a lesion, such as skin ulcers, keloids, hypertrophic and atrophic scars. The collagen type V alpha 2 (COL5A2) gene provides a template for a component of type V collagen, found primarily within the skin basement membrane. Transforming growth factor (TGF)‑β is involved in inflammation, angiogenesis, proliferation of fibroblasts, collagen synthesis and extracellular matrix remodeling. Hypertrophic scar fibroblasts possess a disrupted expression pattern of the TGF‑β signaling compared to normal healing, while an increased TGF‑β signaling reduces the epidermal proliferation rate, triggering atrophic scarring. In the present study, 71 female patients who had undergone planned Caesarean section, without postoperative complications, were examined. These patients were clinically and molecularly evaluated after developing scars in order to determine the role of TGF‑β1 (rs201700967 and rs200230083) and COL5A2 (rs369072636) in pathological scarring. Clinical scar evaluation was carried out using SCAR and POSAS scales and genotyping was performed by RT‑PCR. No statistical differences were found between the subgroups regarding the genotype and the pathological scarring, since all the patients included were wild‑type allele carriers. Further investigations and a more representative study group may highlight the involvement of COL5A2 and TGF‑β1 single nucleotide variants in pathological scarring.
